High drug load buprenorphine microspheres and method of producing same
A sustained release microsphere formulation with a high drug load may be formed by a continuous oil-in-water emulsion process by combining an organic dispersed phase with an aqueous continuous phase. The dispersed phase may include an encapsulating polymer, a primary solvent, such as dichloromethane, a pharmaceutically effective amount of an active agent having a solubility relative to the dispersed phase, and a co-solvent, such as benzyl alcohol, which is capable of increasing the solubility of the active agent relative to the dispersed phase. The continuous phase may include an aqueous solution of polyvinyl alcohol and water.
1. A method of making sustained release microsphere formulation having a high buprenorphine drug load, comprising:
providing a dispersed phase by mixing an encapsulating polymer, a primary solvent, a pharmaceutically effective amount of a salt form of buprenorphine having a solubility relative to the dispersed phase, and a co-solvent capable of increasing the solubility of the buprenorphine relative to the dispersed phase; wherein the ratio of the primary solvent to the co-solvent in the dispersed phase is 2:1 by weight, and wherein the primary solvent is dichloromethane and the co-solvent is benzyl alcohol;
providing a continuous phase comprising an aqueous solution;
mixing the dispersed phase with the continuous phase to form a microsphere formulation; and
preparing a pharmaceutically acceptable microsphere suspension suitable to be delivered to a patient.
2. The method of claim 1 , wherein the encapsulating polymer is selected from the group consisting of poly (D,L-lactide-co-glycolide) and poly(L-lactide).
3. The method of claim 1 , wherein the microsphere formulation has a buprenorphine salt drug load of about 15% by weight of the microspheres to about 55% by weight of the microspheres.
4. The method of claim 1 , wherein the co-solvent is present in an amount of up to 50% by weight of the dispersed phase.
5. The method of claim 1 , wherein the increased solubility of the salt form of buprenorphine relative to the dispersed phase is about 0.001 g/g to about 0.05 g/g.
6. The method of claim 1 , wherein the increased solubility of the salt form of buprenorphine relative to the dispersed phase is about 0.001 g/g to about 0.08 g/g.
7. The method of claim 1 , wherein the increased solubility of the salt form of buprenorphine relative to the dispersed phase is about 0.083 g/g.
8. The method of claim 1 , wherein the encapsulating polymer has an inherent viscosity of about 0.18 η inh dL/g to about 0.54 η inh dL/g.
9. The method of claim 1 , wherein the microsphere formulation has an initial in-vivo burst release of not more than three times the highest concentration observed during the sustained portion of the buprenorphine release.
10. The method of claim 1 , wherein the encapsulating polymer is is poly (D,L-lactide-co-glycolide) and has an inherent viscosity of about 0.20 to about 0.38 η inh dL/g.
11. The method of claim 1 , wherein the microsphere formulation has an initial in-vivo burst release not more than two times the highest concentration observed during the sustained portion of the salt form of buprenorphine release.
12. A sustained release microsphere formulation for injection into a patient prepared by the method recited in claim 1 .
13. A sustained release microsphere formulation for injection into a patient prepared by the method recited in claim 10 .